Table of contents
December 2004 Vol 4 No 12
In this issue
p919 | doi:10.1038/nrc1522
Research Highlights
Receptor tyrosine kinases: Getting on TRK
p920 | doi:10.1038/nrc1519
Metastasis: No way out?
p921 | doi:10.1038/nrc1515
Trial Watch
Learning from kinase-inhibitor trials | Trends in Phase I trials
p921 | doi:10.1038/nrc1516
Kinase inhibitors: Comparison shopping
p922 | doi:10.1038/nrc1511
Kinase inhibition: Life and LYN
p922 | doi:10.1038/nrc1518
Tumour suppressors: Super suppressor
p923 | doi:10.1038/nrc1510
In brief
Protein Kinases | Immunology | Therapeutics | Angiogenesis
p923 | doi:10.1038/nrc1520
Cancer susceptibility: X marks the spot
p924 | doi:10.1038/nrc1513
Drug resistance: Multiple opponents
p924 | doi:10.1038/nrc1514
Protein kinases: REDD or dead?
p925 | doi:10.1038/nrc1517
Metastasis: Causing cancer spread
p926 | doi:10.1038/nrc1512
In the news
UK approves screening embryos for cancer
p926 | doi:10.1038/nrc1521
Focus on: kinases
Reviews
Aurora-kinase inhibitors as anticancer agents
Nicholas Keen & Stephen Taylor
p927 | doi:10.1038/nrc1502
Targeting the mitogen-activated protein kinase cascade to treat cancer
Judith S. Sebolt-Leopold & Roman Herrera
p937 | doi:10.1038/nrc1503
Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors?
Arnaud Besson, Richard K. Assoian & James M. Roberts
p948 | doi:10.1038/nrc1501
Perspective
Timeline
Gefitinib — a novel targeted approach to treating cancer
Roy S. Herbst, Masahiro Fukuoka & José Baselga
p979 | doi:10.1038/nrc1506
Reviews
The role of the unfolded protein response in tumour development: friend or foe?
Yanjun Ma & Linda M. Hendershot
p966 | doi:10.1038/nrc1505
Netrin-1 and its receptors in tumorigenesis
Hirofumi Arakawa
p978 | doi:10.1038/nrc1504
Perspective
Opinion
CpG island methylator phenotype in cancer
Jean-Pierre Issa
p988 | doi:10.1038/nrc1507
